The thesis
PanicFade v4 bets that negative headline shocks are overreacted to and tend to revert toward fundamentals. The rule set is deliberately narrow: buy names where sentiment drops below -0.4 and the tape already confirms panic (RSI14 below 35, price under its SMA20), then size into the weakness. It exits on reversion — RSI14 back above 50 or price reclaiming SMA20 — and hard-stops on fresh lows under continued negativity, treating that as a genuine fundamental break rather than noise.
The design leans on recent sentiment-feedback literature (arXiv:2509.11970, 2025, plus corroborating JRFM/MDPI work) around asymmetric overreaction and reversion. Restricting the universe to 24 mega- and large-cap names — AAPL, MSFT, JPM, XOM, WMT and peers — is a sensible guardrail: mean-reversion is safest where balance sheets and liquidity make "the panic was overdone" a defensible prior.
Recent activity
Activity has been quiet. Across the six most recent scheduled runs (Aug 25 – Sep 1), the strategy executed a single trade: 10 shares of WMT at $103.115 on Aug 28. Every other run reported zero executions and zero rejections. That is the strategy working as intended — it only acts when both sentiment and price-based panic line up, and those conditions simply have not appeared in this window.
The live paper book stands near its $10,000 start: cash of $8,958.54 and total equity of $10,018.24 as of Sep 1, so the WMT position is carrying a small mark-to-market gain. Nothing dramatic, but the account is doing exactly what a patient contrarian should: mostly waiting.
Backtest and validation
The backtest is respectable. Over 1,233 days and 530 trades it returned 37.93% (6.79% CAGR) with a 62.88% win rate, a 9.3% max drawdown, and a Sharpe of 0.96. The validation is the more encouraging story: four walk-forward folds, all four positive, with out-of-sample return of 21.7% and OOS Sharpe of 2.44. Robustness statistics are strong — PSR of 0.985 and a deflated Sharpe of 0.56 across 27 trials, meaning the edge survives a correction for how many variants were tried.
Fold results also trend the right way, from a barely-positive 1.6% in the 2021–22 fold to 21.7% in the most recent — consistent with a strategy that avoided blowing up in a hard tape and did better later.
Strengths and risks
Strengths: clean cross-validation, a sane universe, and event-driven patience that limits overtrading. The risks are real, though. A 0.96 Sharpe and 6.79% CAGR are modest for the effort. Turnover of 5,807% is enormous — fees are small here but slippage would bite live. The 9.3% drawdown is manageable but concentrates in exactly the tail scenarios where "revert toward fundamentals" fails and a shock is real. And the flattering final fold should be read as promising, not predictive. Verdict: a well-constructed, disciplined strategy worth watching — with a wary eye on turnover and regime risk.